Driving Progress in AML

About this episode

Dr. David Sallman discusses advances in acute myeloid leukemia (AML) treatment and patient care.

David Sallman, MD, Moffitt Cancer Center, Tampa, FL Recorded on April 9, 2026 David Sallman, MD Associate Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, FL In this exciting episode, Dr. David Sallman from Moffitt Cancer Center takes a deep dive into acute myeloid leukemia (AML) and the advances transforming patient care. The discussion spans newly approved therapies, including menin inhibitors, as well as promising approaches under investigation in clinical trials, and explores how these innovations are influencing treatment selection, transplantation, and the management of side effects and complications in today’s AML landscape. Tune in today for expert insight into what’s shaping the future of AML care. Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Resources for Patients This episode is supported by Kura Oncology, Inc.

People in this episode

Guest: David Sallman Md

Topics covered

• acute myeloid leukemia
• AML
• patient care
• therapies
• clinical trials

Keywords

• menin inhibitors
• treatment selection
• transplantation
• side effects
• complications

Mentioned in this episode

Products: menin inhibitors

Places: Tampa, FL

More episodes of Treating Blood Cancers

• Optimizing HSCT in Blood Cancers · June 2, 2026 · 39 min
• Clinical Strategies for Supporting Couples, Care Partners, and Families in Oncology Care · May 8, 2026 · 35 min
• Redefining Normal: Clinical Insights for Healthcare Professionals Supporting Survivors After Treatment · April 13, 2026 · 34 min
• Optimizing Outcomes in Myeloma · March 24, 2026 · 40 min
• Strategies to Navigate Expanded Access (Compassionate Use) in Treating Pediatric Oncology · March 3, 2026 · 40 min
• What’s New and What’s Next in CLL · February 17, 2026 · 39 min